Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
SUTRO BIOPHARMA, INC. roe for the quarter ending 2026-06-30 was 174.84%, a 73.10% decline year-over-year.
SUTRO BIOPHARMA, INC. roe for the quarter ending 2026-03-31 was 229.64%, a 75.83% decline year-over-year.
SUTRO BIOPHARMA, INC. roe for the quarter ending 2025-12-31 was 144.27%, a change of 654.26% year-over-year.
SUTRO BIOPHARMA, INC. roe for the quarter ending 2025-09-30 was 248.39%, a change of 359.84% year-over-year.
SUTRO BIOPHARMA, INC. roe for fiscal 2025 was 144.27%, a change of 654.26% from fiscal 2024.
SUTRO BIOPHARMA, INC. roe for fiscal 2024 was -509.99%, a change of -438.63% from fiscal 2023.
SUTRO BIOPHARMA, INC. roe for fiscal 2023 was -71.36%, a change of -16.44% from fiscal 2022.
SUTRO BIOPHARMA, INC. roe for fiscal 2022 was -54.92%, a change of -13.13% from fiscal 2021.